Antisense therapy in oncology: new hope for an old idea?
- 1 August 2001
- journal article
- review article
- Published by Elsevier BV in The Lancet
- Vol. 358 (9280), 489-497
- https://doi.org/10.1016/s0140-6736(01)05629-x
Abstract
No abstract availableKeywords
This publication has 67 references indexed in Scilit:
- Livin, a Novel Inhibitor of Apoptosis Protein Family MemberJournal of Biological Chemistry, 2001
- Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16INK4a and Cdk2/Cyclin E complex activationOncogene, 2000
- Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA componentOncogene, 2000
- High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastomaOncogene, 2000
- The Bcl-2 Protein Family: Arbiters of Cell SurvivalScience, 1998
- Antisense Oligonucleotides Demonstrate a Dominant Role of c-Ki-RAS Proteins in Regulating the Proliferation of Diploid Human FibroblastsPublished by Elsevier BV ,1996
- Bias in Nucleotide Composition of Antisense OligonucleotidesAntisense and Nucleic Acid Drug Development, 1996
- Telomerase as a Potential Molecular Target to Study G-Quartet PhosphorothioatesAntisense and Nucleic Acid Drug Development, 1996
- Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistanceCurrent Opinion in Oncology, 1995
- Heat shock resistance conferred by expression of the human HSP27 gene in rodent cells.The Journal of cell biology, 1989